OncoSec Medical (NASDAQ:ONCS) Now Covered by StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of OncoSec Medical (NASDAQ:ONCSGet Rating) in a note issued to investors on Sunday. The firm set a “sell” rating on the biotechnology company’s stock.

OncoSec Medical Stock Down 4.3 %

Shares of NASDAQ ONCS opened at $0.74 on Friday. The firm’s 50-day simple moving average is $0.80 and its 200 day simple moving average is $0.90. The company has a market cap of $29.00 million, a price-to-earnings ratio of -0.78 and a beta of 1.98. OncoSec Medical has a 12-month low of $0.67 and a 12-month high of $2.42.

OncoSec Medical (NASDAQ:ONCSGet Rating) last issued its quarterly earnings results on Tuesday, June 14th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.02. On average, equities analysts expect that OncoSec Medical will post -0.72 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ONCS. Long Focus Capital Management LLC acquired a new position in OncoSec Medical during the 4th quarter valued at about $66,000. Salzhauer Michael lifted its position in OncoSec Medical by 15.9% during the 4th quarter. Salzhauer Michael now owns 321,354 shares of the biotechnology company’s stock valued at $308,000 after purchasing an additional 44,042 shares during the period. Finally, Bank of New York Mellon Corp lifted its position in OncoSec Medical by 653.7% during the 1st quarter. Bank of New York Mellon Corp now owns 386,074 shares of the biotechnology company’s stock valued at $444,000 after purchasing an additional 334,849 shares during the period. 13.98% of the stock is currently owned by institutional investors and hedge funds.

About OncoSec Medical

(Get Rating)

OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor.

Featured Articles

Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.